Showing all 16 results

  • Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate)

    $780.00 – $1,077.01

    Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) is a medication used for the long term, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

    Select optionsDone

  • Clenbuterol

    $1,010.57

    Clenbuterol is a medication used for the treatment of people with bronchial asthma, chronic bronchitis, emphysema, acute bronchitis, or stress urinary incontinence.

    Physicians sometimes prescribe Clenbuterol for off-label treatment of people suffering from ALS.

    Clenbuterol was previously known under the brand name TONIL (clenbuterol).

    100 tablets of 10 microgram (μg)

    Add to cartDone
  • Emgality

    Emgality

    $952.80 – $1,652.80
    Emgality represents a promising development in the treatment of several neurological conditions, including chronic migraines, cluster headaches, and post-traumatic headache.
    Its advanced mechanism of action and low rate of side effects, Emgality has become an attractive option for individuals who are seeking a safe and effective treatment for these conditions.
    Select optionsDone

  • Kaftrio (elexacaftor/tezacaftor/ivacaftor)

    $12,950.00 – $16,057.00

    Kaftrio (elexacaftor/tezacaftor/ivacaftor) is a medication used in combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

    Select optionsDone

  • Kalydeco (ivacaftor)

    $7,981.00 – $18,006.99

    Kalydeco (ivacaftor) is a medicine indicated for the treatment of patients with cystic fibrosis (CF) aged 4 months and older who have at least one mutation in their CF gene that is responsive to Kalydeco.

    Select optionsDone

  • Ketas (ibudilast)

    $504.70 – $868.70

    Ketas (ibudilast) is a medication used for the treatment of bronchial asthma and for cerebrovascular (brain and blood vessel) disorders.

    Ibudilast has received orphan drug status for the treatment of patients affected by amyotrophic lateral sclerosis (ALS) by EMA and FDA.

    Select optionsDone

  • Lucaftor (lumacaftor/ivacaftor)

    $2,730.82

    Lucaftor (lumacaftor/ivacaftor) is a medicine indicated for the treatment of cystic fibrosis (CF) in patients 12 years and older who have two copies of the F508del mutation (F508del/F508del) in the CFTR gene.

    200/125 mg

    Add to cartDone

  • Symdeko (tezacaftor / ivacaftor)

    $43,126.00

    Symdeko (tezacaftor/ivacaftor) is a medicine for the treatment of patients with cystic fibrosis (CF) aged 6 years and older. It is available in tablet form each containing 100 mg of tezacaftor and 150 mg of ivacaftor. It is indicated in combination with another medicine containing 150 mg ivacaftor alone.

    It is commercialized in Europe under the brand name Symkevi and in United States under the brand name Symdeko.

    28 tablets of 100 mg/150 mg

    Add to cartDone

  • Symkevi (tezacaftor/ivacaftor)

    $4,996.95

    Symkevi (tezacaftor/ivacaftor) is a medicine for the treatment of patients with cystic fibrosis (CF) aged 12 years and older. It is available in tablet form each containing 100 mg of tezacaftor and 150 mg of ivacaftor. It is indicated in combination with another medicine containing 150 mg ivacaftor alone.

    28 tablets of 100 mg/150 mg

    It is commercialized in Europe under the brand name Symkevi and in United States under the brand name Symdeko.

    Add to cartDone

  • Tezspire (tezepelumab-ekko)

    $1,633.00 – $2,433.00

    Tezspire (tezepelumab-ekko) is an add-on maintenance treatment used to treat adult and paediatric patients aged 12 years and older with severe asthma.

    Select optionsDone

  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

    $923.00 – $1,423.00

    Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a medication used for the long term, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.

    Select optionsDone

  • Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor)

    $34,702.27

    Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) is a medication used for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to Trikafta based on in vitro data.

    Add to cartDone

  • Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)

    $11,723.88

    Trixacar (elexacaftor/tezacaftor/ivacaftor) is a medication used for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

    60 tablets of elexacaftor/tezacaftor/ivacaftor + 30 tablets of ivacaftor

    Add to cartDone
  • Vabysmo Faricimab Svoa

    Vabysmo Faricimab Svoa

    $3,971.50

    Vabysmo Faricimab Svoa is a prescription medicine that is used to treat two leading causes of vision loss: neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME).

    One of the key advantages of Vabysmo (Faricimab-Svoa) is its long duration of action. Unlike many other treatments that require frequent injections, Vabysmo need only be administered once every two to three months. One vial of 120 mg/mL

    Add to cartDone
  • Vijoice

    Vijoice

    Vijoice (alpelisib) represents a significant advancement in the treatment of HR+/HER2- breast cancer.

    Its highly targeted mechanism of action, favorable safety profile, and demonstrated efficacy make it an important addition to the armamentarium of treatments available for patients with advanced or metastatic breast cancer.

    Read moreDone

  • Yupelri (revefenacin)

    $9,230.00

    Yupelri (revefenacin) is a nebulized maintenance medicine used to treat chronic obstructive pulmonary disease (COPD.

    175 μg/3 mL

    Add to cartDone